Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi

Stock Information for Ventyx Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Ventyx Biosciences Inc.

Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson's Disease
Ventyx Biosciences Announces Departure of Chief Financial Officer
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress
Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Participants with Moderately to Severely Active Crohn's Disease
ONGOING INVESTIGATION: Scott+Scott Attorneys at Law LLP Investigates Ventyx Biosciences, Inc.'s Directors and Officers for Breach of Fiduciary Duties - VTYX
ONGOING INVESTIGATION NOTICE: Scott+Scott Attorneys at Law LLP Investigates Ventyx Biosciences, Inc.'s Directors and Officers for Breach of Fiduciary Duties - VTYX
VENTYX SHAREHOLDER NOTICE: Ventyx's (VTYX) Board is Being Investigated for Insider Trading Allegations, Long-Term Investors Are Notified to Contact the Firm for Details

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.